Mutant Peptides And Methods Of Treating Subjects Using The Same
AssigneePrince Biotech, LLC
InventorEytan R. Barnea
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating autoimmune disease using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.
Claims21
A composition comprising a PIF analog comprising an amino acid sequence that is at least 93% homologous to SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, or a pharmaceutically acceptable salt thereof.
A method of treating or preventing autoimmune disease in a subject in need thereof, the method comprising administering to the subject at least one pharmaceutical composition comprising:
- i) a therapeutically effective amount of a pre-implantation factor (PIF) analog, or a pharmaceutically acceptable salt thereof;
- and
- ii) a pharmaceutically acceptable carrier.
A method of treating or preventing diabetes in a subject in need thereof, the method comprising administering to the subject at least one pharmaceutical composition comprising:
- i) a therapeutically effective amount of a pre-implantation factor (PIF) analog, or a pharmaceutically acceptable salt thereof;
- and
- ii) a pharmaceutically acceptable carrier.
A method of binding an insulin degrading enzyme (IDE) in a subject in need thereof, the method comprising administering to the subject at least one pharmaceutical composition comprising:
- i) a therapeutically effective amount of a pre-implantation factor (PIF) analog, or a pharmaceutically acceptable salt thereof;
- and
- ii) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.